𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma

✍ Scribed by Monica M. Mita; Eric K. Rowinsky; Leonardo Forero; S. Gail Eckhart; Elzbieta Izbicka; Geoffrey R. Weiss; Muralidhar Beeram; Alain C. Mita; Johann S. de Bono; Anthony W. Tolcher; Lisa A. Hammond; Paul Simmons; Kristin Berg; Chris Takimoto; Amita Patnaik

Publisher
Springer
Year
2006
Tongue
English
Weight
353 KB
Volume
59
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A phase II study of spirogermanium in pa
A phase II study of spirogermanium in patients with metastatic malignant melanoma
✍ Elizabeth Eisenhauer; Ian Kerr; Audley Bodurtha; Neill Iscoe; Peter McCulloch; K πŸ“‚ Article πŸ“… 1985 πŸ› Springer US 🌐 English βš– 205 KB

The National Cancer Institute of Canada Clinical Trials Group conducted a phase II study of spirogermanium given daily for 5 days every 3 weeks to previously untreated patients with malignant melanoma. In 21 evaluable patients one complete response was seen (response rate 5%). Disease progression oc

Temozolomide plus thalidomide in patient
Temozolomide plus thalidomide in patients with brain metastases from melanoma : A Phase II study
✍ Wen-Jen Hwu; Eric Lis; Jennifer H. Menell; Katherine S. Panageas; Lynne A. Lamb; πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 98 KB

## Abstract ## BACKGROUND Temozolomide plus thalidomide is a promising oral combination regimen for the treatment of metastatic melanoma. The current Phase II study examined the efficacy and safety of this combination in chemotherapy‐naive patients with brain metastases. ## METHODS Patients with

A Phase I and pharmacokinetic study of h
A Phase I and pharmacokinetic study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma
✍ Edward F. McClay; Mary-Eileen T. McClay; Jeffery A. Jones; Paul J. Winski; Rando πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 97 KB πŸ‘ 2 views

by 40 mg to the MTD in groups of 3 patients. DDP (80 mg/m 2 ) was begun on Day ogy/Oncology, Hollings Cancer Center, Medical 2 and repeated weekly for a total of 3 weeks. During Week 4, the patients were University of South Carolina, Charleston, South not treated with DDP but instead evaluated for r